Back to search

Article

INCIDENCE AND ASSOCIATED FACTORS WITH THE CHANGE FREE TIME BETWEEN THE BRANDED OR GENERIC IMATINIB IN NAIVE PATIENTS WITH CHRONIC MYELOID LEUKEMIA

2023-04-06

Abstract excerpt

<h4>Purpose: </h4> to determine the incidence of switching and the factors associated with the switch-free time of brand or generic imatinib. <h4>Methods: </h4>: analytical, dynamic cohort, observational, prospective study, between January-2017 and January-2022. The exposed group was patients with brand drugs and the non-exposed with generic with 83 patients in each group. The dependent variable was switching fro...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
0ef147b9-b1b1-5330-85ae-af91536153e8
DOI
10.22541/au.168075544.47980416/v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
INCIDENCE AND ASSOCIATED FACTORS WITH THE CHANGE FREE TIME BETWEEN THE BRANDED OR GENERIC IMATINIB IN NAIVE PATIENTS WITH CHRONIC MYELOID LEUKEMIADOI 10.22541/au.168075544.47980416/v1
Efficacy, Safety, Cost, and Clinical Outcomes After the Switch to Generic Rosuvastatin Compared with Consistent Brand-Name Atorvastatin Treatment.Semantic proximity
Real-world treatment adherence and persistence of FLT3 inhibitors as post-alloHCT maintenance therapy in patients with AML in the United States: a cohort study using administrative claims data.Semantic proximity
The importance of real-world data in evaluating the safety of biosimilars: a descriptive study of clinical practice in an oncohematological population.Semantic proximity
Impact of a Guaranteed Access Program to Imatinib on the Survival of Patients with Chronic Myeloid LeukemiaSemantic proximity
Calendar Period Estimation of Probabilities of Transition in Drug DevelopmentSemantic proximity
Efficacy and Tolerability of Generic Pirfenidone After Switch from Esbriet® in Idiopathic Pulmonary Fibrosis: A Real-World Observational StudySemantic proximity
Impact of Genetic Mutations and Health Plan Access to Therapies on Treatment Response and Drug Costs Related to Tyrosine Kinase Inhibitor Treatment Among Patients With Chronic Myelogenous Leukemia.Semantic proximity
Analysis of Antibiotic Exposure and Development of Acute Graft-vs-Host Disease Following Allogeneic Hematopoietic Cell TransplantationSemantic proximity
Availability of Different Branded Generic Vildagliptin after Off-patenting: An Observation from Eastern IndiaSemantic proximity
Genetic and Non-genetic Correlates of Imatinib Pharmacokinetics and Side Effects of Imatinib in Palestinian Patients with Chronic Myeloid Leukemia.Semantic proximity
Interplay of mutations, alternate mechanisms, and treatment breaks in leukaemia: Understanding and implications studied with stochastic models.Semantic proximity
Time to Patients’ Access to New Medicines in Greece: Evaluation of Health Technology Assessment (HTA) Process from July 2018 until January 2021.Semantic proximity
Select a neighboring publication to make it the new centre.